KaiNETIC-2: KAI-9531 once weekly in adults with obesity or overweight and type 2 diabetes mellitus

Phase 3, randomised, double-blind trial in obesity, Overweight and type 2 diabetes mellitus (T2DM) comparing KAI-9531 once weekly with Placebo once weekly (2 arms). Primary endpoints: Percent change in body weight from baseline at Week 76 and Change in hemoglobin A1c from baseline at Week 76. Planned start Jun 2026; status: authorised.